Cited by 188Neuroinflammation and Neurodegeneration MechanismsAlzheimer's disease research and treatmentsNeurological Disease Mechanisms and Treatments

Co-expression patterns of microglia markers Iba1, TMEM119 and P2RY12 in Alzheimer’s disease

Open access
Kenkhuis, Boyd, Somarakis, Antonios, Kleindouwel, Lynn R.T., van Roon-Mom, Willeke M.C., Höllt, Thomas, van der Weerd, Louise·2022·Neurobiology of Disease

Published version of a preprint

Abstract

Microglia have been identified as key players in Alzheimer's disease pathogenesis, and other neurodegenerative diseases. Iba1, and more specifically TMEM119 and P2RY12 are gaining ground as presumedly more specific microglia markers, but comprehensive characterization of the expression of these three markers individually as well as combined is currently missing. Here we used a multispectral immunofluorescence dataset, in which over seventy thousand microglia from both aged controls and Alzheimer patients have been analysed for expression of Iba1, TMEM119 and P2RY12 on a single-cell level. For all markers, we studied the overlap and differences in expression patterns and the effect of proximity to β-amyloid plaques. We found no difference in absolute microglia numbers between control and Alzheimer subjects, but the prevalence of specific combinations of markers (phenotypes) differed greatly. In controls, the majority of microglia expressed all three markers. In Alzheimer patients, a significant loss of TMEM119+-phenotypes was observed, independent of the presence of β-amyloid plaques in its proximity. Contrary, phenotypes showing loss of P2RY12, but consistent Iba1 expression were increasingly prevalent around β-amyloid plaques. No morphological features were conclusively associated with loss or gain of any of the markers or any of the identified phenotypes. All in all, none of the three markers were expressed by all microglia, nor can be wholly regarded as a pan- or homeostatic marker, and preferential phenotypes were observed depending on the surrounding pathological or homeostatic environment. This work could help select and interpret microglia markers in previous and future studies.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.nbd.2022.105684

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 1

  1. Butovsky, O., Jedrychowski, M.P., Moore, C.S., Cialic, R., Lanser, A.J., Gabriely, G., et al., 2013. Identification of a unique TGF-β-dependent molecular and functional signature in microglia. Nat. Neurosci. 17 (1), 131-143.

Cited by

Sorted by citations

Authors
Kenkhuis, B., Somarakis, A., Kleindouwel, L. R. T., van Roon-Mom, W. M. C., Höllt, T., & van der Weerd, L.
Affiliations
Leiden University Medical Center (NL)
Corresponding author
Kenkhuis, Boyd
Venue
Neurobiology of Disease
Publisher
Elsevier BV
Published
2022-06
Volume
167
Pages
105684
ISSN
0969-9961 (ISSN-L)
OpenAlex
W4221040770
Cited by
188
References
33
Citations by year
2026: 40 · 2025: 55 · 2024: 54 · 2023: 24 · 2022: 15
FWCI
13.27
Type
journal article
Language
en
Open access
Locations
  • Neurobiology of Disease (publishedVersion, cc-by-nc-nd)
  • bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion, cc-by-nd)
  • PubMed (publishedVersion)
  • Leiden Repository (Leiden University) (submittedVersion, cc-by-nc-nd)
  • Data Archiving and Networked Services (DANS) (submittedVersion, cc-by-nc-nd)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Research Repository (Delft University of Technology) (submittedVersion)
Funders
  • Netherlands Organisation for Scientific Research
  • Alzheimer Netherlands
Topics
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Life Sciences › Neuroscience › Neurology › Neurological Disease Mechanisms and Treatments
Keywords
microglia, Alzheimer's disease, Iba1, TMEM119, P2Y12 receptor, microglial markers, microglial phenotype, amyloid plaques, microglial heterogeneity, single-cell gene expression, microglial homeostasis
MeSH terms
Aged, Alzheimer Disease, Calcium-Binding Proteins, Humans, Membrane Proteins, Microfilament Proteins, Biomarkers, Amyloid beta-Peptides, Microglia, Plaque, Amyloid, Receptors, Purinergic P2Y12

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review